Thirteenth London International Cough Symposium (LICS 2024): Highlighted the development of novel antitussive therapies and advanced cough monitoring technologies.
ERS Congress 2024:
Cough was a hot topic, with one of the busiest poster sessions, running overtime due to high interest.
The 8th IPF Summit: "Cough is a sleeper biomarker in idiopathic pulmonary fibrosis (IPF)".
Validation Trial Success: Hyfe’s validation trial showing 90% sensitivity to fully automated real-time cough monitoring of problematic cough in real world environments.
Broad Application in Clinical Trials: Hyfe’s cough monitoring capabilities are used in Phase 1, Phase 2b, and Real World Evidence (RWE) clinical trials, as well as 49 research studies.
Prolific Research Output This Year: 5 new peer-reviewed publications, 5 white-papers, 3 pre-prints, and over 15 poster presentations featuring Hyfe’s cough monitoring technology.
Regulatory Milestones: Hyfe is on track for De Novo FDA clearance in 2025.
Digital Therapeutics (DTx) for Chronic Cough: First evidence of the novel digital therapeutic (DTx) for chronic cough, developed by Hyfe and industry collaborators.
Expanding Evidence Base: Expecting explosive growth of evidence of cough as a valuable biomarker across multiple therapeutic areas.
Looking back on 2024, we’re proud of the progress made and excited to keep pushing boundaries in cough science and innovation in 2025!
Share post:
Our website use cookies. By continuing navigating, we assume your permission to deploy cookies as detailed in our Privacy Policy.
